1 The pharmacological features of rat white adipocyte b-adrenoceptor subtypes were investigated by saturation and b-agonist competition studies with [ 6 The lipolytic response to 0.001 mM BRL was inhibited by both, selective b 1 -and b 2 -antagonist, in a monophasic manner with low potencies (CGP 20712A pK i : 54.5 and ICI 118551 pK i : 5.57+0.13). Similar monophasic pro®les were obtained for inhibition of Xam-and Dob-induced lipolysis. In this case, CGP 20712A was more potent (410 times) than ICI 118551. The monophasic inhibition was also observed with ICI 118551 in the presence of 0.05 mM Iso or 0.13 mM NA. In contrast, two populations of sites were identi®ed with CGP 20712A in the presence of Iso as well as NA. The pK i values for the ®rst sites were 8.41+0.09 and 8.58+0.17, respectively, and for the second population of sites 4.73+0.22 and 4.27+0.27, respectively. The proportion of the ®rst sites was low: 19+4 and 22+5%, respectively. Biphasic curves were obtained with both antagonists using 2.5 mM Proc (CGP 20712A: pK i 1: 8.17+0.08, site1: 23+6%, pK i 2: 4.77+0.14; ICI 118551: pK i 1: 7.78+0.03, site1: 37+2%, pK i 2: 5.35+0.25). 7 Our results show that the radioligand [ 3 H]-CGP 12177 allows the characterization of b 1 -and b 3 -adrenoceptor subtypes on rat white adipocytes. Lipolysis is highly dependent on b 1 -and b 3 -adrenoceptors. Finally, binding and functional studies con®rm that lipolysis is mainly driven by the b 3 -subtype.
Introduction
The lipolytic eects of catecholamines (noradrenaline, adrenaline) on adipocytes are primarily mediated by b-adrenoceptors. Adipocyte b-adrenoceptors were ®rst subclassi®ed as the b 1 -subtype by relative lipolytic potencies of several classical b-agonists (Lands et al., 1967) as well as by radioligand binding studies (Bojanic & Nahorski, 1983; Bahout & Malbon, 1988) . Pharmacological analysis of the b-adrenoceptor-mediated metabolic responses of rat adipocytes suggested the existence of a third b-adrenoceptor, often called atypical badrenoceptor according to its metabolic and pharmacological features (De Vente et al., 1980; Wilson et al., 1984; Bojanic et al., 1985) . Three pharmacological characteristics are well established (Arch & Kaumann, 1993) . First, usual b-adrenoceptor antagonists display a weak capacity to inhibit lipolysis in rat adipocytes (De Vente et al., 1980; Wilson et al., 1984; Langin et al., 1991; Van Liefde et al., 1992) . Second, the rodent adipocytes are more responsive to the novel b-agonists, such as BRL 37344, compared to classical b-agonists acting on b 1 -and b 2 -adrenoceptor subtypes (Wilson et al., 1984; Hollenga & Zaagsma, 1989; Langin et al., 1991) . Finally, some antagonists of b 1 -and b 2 -receptors, such as CGP 12177, are, at higher concentrations, partial agonists of lipolytic function (Langin et al., 1991; Van Liefde et al., 1992) .
The b-adrenoceptor classi®cation has been, at last, modi®ed since the gene coding for the human (Emorine et al., 1989) , rat (Granneman et al., 1991; Muzzin et al., 1992) and mouse b 3 -receptor was cloned and expressed in Chinese hamster ovary cells. Currently, the coexistence of three b-adrenoceptor subtypes is sustained by the identi®cation of three subtypes of b-adrenoceptor mRNA in rodent white adipocytes (b 1 -, b 2 -and b 3 -receptor mRNA), with b 3 -adrenoceptor mRNA being expressed predominantly (Muzzin et al., 1991; Collins et al., 1994) . However, functional studies have demonstrated that only the b 1 -and b 3 -receptor subtypes can stimulate lipolysis in rat (Hollenga & Zaagsma, 1989; Van Liefde et al., 1992; Murphy et al., 1993) . Furthermore, catecholamine-induced lipolysis is mediated predominantly by b 3 -receptors in rat white adipocytes (Hollenga & Zaagsma, 1989; Van Liefde et al., 1992; Murphy et al., 1993; Bousquet-MeÂ lou et al., 1994) .
While functional studies on rat white adipocytes revealed a major role for b 3 -adrenoceptors and a minor role for b 1 -receptors, the b 3 -subtype has not been detected by binding studies on these cells. Although the ligands commonly used until now for b-adrenoceptor identi®cation ( (Arch & Kaumann, 1993) , one of them ([ 3 H]-CGP 12177, b 1 /b 2 -antagonist and b 3 -partial agonist) permitted the characterization of the b 3 -subtype by binding studies on human and garden dormouse white adipocytes (Revelli et al., 1993; CarpeÂ neÂ et al., 1994) , in homogenates of rat brown adipose tissue (Muzzin et al., 1992) , of rat brown adipocytes (D'Allaire et al., 1995) and 3T3-F442A adipocytes (FeÁ ve et al., 1991) . Although comparable studies were not successful for rat white adipocytes (Langin et al., 1991) , several binding studies previous to 1990 had shown a heterogeneity of b-adrenoceptors on these cells suggesting the coexistence of two populations of sites with diering anities for some b-adrenoceptor radioligands and for several b-adrenoceptor competitors (Giudicelli et al., 1979; Bahout & Malbon, 1988) . The ®rst population was identi®ed as a b 1 -subtype, but no explanation was given for the second population of binding sites. Up to date, no investigation has established clearly a relationship between lipolytic function and binding studies on rat white adipocytes. Another point of uncertainty is the role of b 2 -adrenoceptors in the lipolysis of rat white adipocytes.
The aim of the present study was to characterize the badrenoceptor subtypes on rat white adipocytes by saturation and b-agonist competition studies with the radioligand [ 3 H]-CGP 12177. We also assessed the lipolytic activity of the bagonists used for competition studies and the inhibition of their activity by CGP 20712A (selective b 1 -antagonist) or ICI 118551 (selective b 2 -antagonist). The binding anities of b-agonists for b-adrenoceptor subtypes were compared with their potencies in activating b-adrenoceptor-mediated lipolysis.
Methods

Isolation of adipocytes
Adipocytes were prepared according to the method of Rodbell (1964) with minor modi®cations. Male Wistar rats (200 ± 250 g) were fed ad libitum and killed by a blow on the head. Epididymal fat pads were removed, cut into small pieces and incubated with 0.1% collagenase in Krebs-Ringer buer supplemented with 20 mM HEPES, 1.4 mM CaCl 2 and 3% bovine serum albumin, pH 7.4, for 60 min at 378C in a shaking waterbath. After collagenase digestion, the adipocytes were separated by ®ltration through nylon cloth (mesh=200 mm) and then washed 3 times with a supplemented Krebs-Ringer buer by centrifugation (400 g, 5 min). The adipocyte suspension was divided into two aliquots for lipolysis measurement and binding studies.
Crude membrane preparation
Adipocytes were lysed at room temperature in hypotonic medium containing 2 mM Tris-HCl, 2.5 mM MgCl 2 , 1 mM KHCO 3 , 100 mM EGTA, pH 7.5, and the following protease inhibitors: 10 mg ml 71 leupeptin and 300 mM phenylmethylsulphonyl¯uoride, then centrifuged for 15 min at 40 000 g at 158C. The pellet was resuspended in 40 ml of binding buer (50 mM Tris-HCl, 0.5 mM MgCl 2 , pH 7.5) and again centrifuged (40 000 g for 15 min at 48C). The resulting pellet was resuspended in binding buer to a ®nal concentration of 2 ± 3 mg protein ml 71 and stored at 7808C for subsequent binding studies. Protein concentration was determined by the dye-binding assay with a commercial kit (Bio-Rad, MuÈ nchen, Germany) and bovine serum albumin was used as standard.
Binding studies
For saturation studies, [
3 H]-CGP 12177 was used at concentrations ranging from 0.3 to 100 nM. To the binding buer containing 100 mM GTP, 50 ml ligand and 50 ml crude membranes (equivalent to 50 ± 80 mg protein) were added to obtain a ®nal volume of 200 ml. Competition studies were performed with 15 nM [ 3 H]-CGP 12177 in the presence of catecholamines, isoprenaline (Iso), noradrenaline (NA) and adrenaline (Ad), the selective b 3 -agonist, BRL 37344 (BRL) and a selective b 1 -agonist, xamoterol (Xam) as well as a b-antagonist, propranolol. With the selective b 2 -agonist, procaterol (Proc), [
3 H]-CGP 12177 was used at 2 nM. The mixture was incubated in a shaking waterbath at 378C for 30 min and the reaction was stopped by the addition of 4.5 ml cold binding buer immediately followed by ®ltration under vacuum through Whatman GF/C glass-®bre ®lters (Maidstone, U.K.) by use of a Millipore apparatus (Bedford, MA, U.S.A.). Filters were rapidly washed with 15 ml cold binding buer. The radioactivity trapped by ®lters was measured with a liquid scintillation counter (LS6000SC, Beckman, U.S.A.). In saturation experiments, non speci®c binding was determined in the presence of 100 mM propranolol. This concentration was generally used to characterize all b-adrenoceptor subtypes on adipocytes other than rat white adipocytes (Muzzin et al., 1992; Sillence et al., 1993; Revelli et al., 1993) .
Lipolysis measurements
Adipocytes (2 ± 3610 5 cells) were incubated with pharmacological agents at suitable dilutions in a ®nal volume of 500 ml. Lipolysis was assessed by use of selective b-agonists and the catecholamines, most of which were also used in competition studies (Iso, NA, Ad, BRL, CGP 12177, Dob, Xam and Proc) . When the selective b 1 -antagonist CGP 20712A and the selective b 2 -antagonist ICI 118551 were used, cells were preincubated for 15 min with the antagonist before addition of the b-agonist. In ®rst set of experiments, the high agonist concentrations used of Iso (1 mM), BRL (0.01 mM), Xam (10 mM), Dob (10 mM) and Proc (10 mM), allowed the recruitment of all b-adrenoceptor subtypes implicated in lipolysis stimulation (Granneman, 1992; CarpeÂ neÂ et al., 1993; Bousquet-MeÂ lou et al., 1994) . Hollenga et al. (1990) showed that CGP 20712A did not antagonize the BRL-induced lipolysis between 10 nM to 10 mM whereas it induced a small but consistent rightward shift of the Iso concentration-response curve, indicating that this antagonist had no anity for the b 3 -adrenoceptor subtype up to 10 mM; at 10 mM, only b 1 -adrenoceptor-mediated stimulation was inhibited. Investigation of the accumulation of adenosine 3' : 5'-cyclic monophosphate (cyclic AMP) and lipolytic activity in rat brown adipocytes gave similar results (Nicoli et al., 1995) . The b 2 -antagonist, ICI 118551 (10 mM and higher), antagonized the Iso-and BRLinduced lipolysis; thus, at these concentrations, this antagonist counteracted the responses induced by activation of all badrenoceptor subtypes (Hollenga et al., 1990) . Langin et al. (1991) made the same observations with BRL induced-lipolysis. Thus, agonist-induced lipolysis was determined with 10 mM CGP 20712A and 1 mM and 5 mM ICI 118551. In a second run of experiments, the eects of concentrations of agonists close to their EC 50 values (Iso 0.5 mM, NA 1.3 mM, BRL 0.001 mM, Xam 5 mM, Dob 2.0 mM and Proc 2.5 mM), were counteracted by both antagonists in the concentration range 10 710 to 10 74 M. Incubations were carried out at 378C in a shaking waterbath. After a 90 min incubation, the reaction was stopped by plunging the tubes into an ice bath. After centrifugation (2000 g at 48C for 10 min), an aliquot of the infranatant was taken to evaluate enzymatically the concentration of glycerol released during the incubation (Glycerol assay kit; Boehringer, Mannheim, Germany).
Data and statistical analysis
Results are expressed as means+s.e.mean. The binding parameters (K d , B max and K i ) were determined by using LIGAND, a non-linear curve-®tting programme (Munson & Rodbard, 1980) . The statistical method given by the LIGAND programme was used to determine whether the saturation and displacement curves were best ®tted by a one-or two-site model. Concentration-response curves for glycerol release as a function of agonist and antagonist concentration were analysed by computer-assisted iteration with GraphPad PRISM (San Diego, CA, U.S.A.). For other data treatments, statistical signi®cance was determined by analysis of variance (ANOVA). A two-tailed P value 50.05 was considered to be statistically signi®cant. 
Drugs and chemicals
Results
Saturation binding study
Experiments on rat white adipocyte membranes generated a saturation binding curve for [
3 H]-CGP 12177 that was clearly biphasic (Figure 1a ). Although linear with increasing concentrations of [ 3 H]-CGP 12177 (data not shown), the non speci®c binding de®ned in the presence of 100 mM propranolol reached about 60% of total binding for 100 nM radioligand. A Scatchard plot of these data was curvilinear indicating the presence of two binding sites ( Figure 1b) . Indeed, analysis by LIGAND con®rmed that the data ®tted a two-site model (P50.001). The binding characteristics are shown in Table 1 . Low anity binding sites were mainly expressed on rat white adipocytes (about 90% of total badrenoceptors).
Competition studies with b-adrenoceptor ligands
All competition and saturation studies were performed in the presence of 100 mM GTP to shift all receptor subtypes into the low anity state for agonists (Kent et al., 1980) . To label both, high and low anity binding sites, the studies were performed with 15 nM [ 
b-Adrenoceptor subtype expression and functioncompeted with high eciency for the predominant population of [ 3 H]-CGP 12177 binding sites, whereas at the same concentration NA, Ad and Iso inhibited radioligand binding from only a minor population of sites. The relative order of potency for competition with [
3 H]-CGP 12177 from its high anity binding sites was: Iso4NA4Ad44BRL, and from its low anity binding sites was: BRL44Iso5NA4Ad. These rank orders suggest that the high and low anity b-adrenoceptors on rat white adipocytes are b 1 -and b 3 -subtypes, respectively.
With regard to the selective b 1 -agonist Xam, only one population of sites was identi®ed (Figure 2c ) since the competition curve was best ®tted to a one-site model (P50.001). The B max value indicated that the binding sites were the minor population of b-adrenoceptors and thus probably represented the b 1 -subtype ( Table 2 ).
The capacity of Proc, a selective b 2 -agonist, to inhibit 
Lipolytic activity of b-agonists
To investigate the contribution of each b-adrenoceptor subtype to the induction of lipolysis, the functional eect of different b-agonists was examined. The dose-dependent stimulating eect of various b-agonists on glycerol release by rat white adipocytes is shown in Figure 4 . The pD 2 and E max values of lipolytic function are given in Table 3 .
The most potent inducer of lipolysis was the selective b 3 -agonist, BRL. It was 65, 150 and 560 times more potent than Iso, NA and Ad, respectively (Figure 4a and b; Table 3 ). The rank order of agonist potency to induce lipolysis was BRL44Iso4NA4Ad, which paralleled the ability of these agonists to compete with [ 3 H]-CGP 12177 for its low anity binding sites. CGP 12177 (b 1 -and b 2 -antagonist) showed (Figure 4b, Table 3 ) features of a partial b 3 -agonist inducing lipolysis with lower ecacy than BRL and the b-agonist, Iso.
Xam is known to be a partial selective b 1 -agonist (Nuttall & Snow, 1982; Malta et al., 1985) . We also used another selective b 1 -agonist, Dob. These two selective b 1 -agonists elicited different lipolytic activities. Xam exhibited the functional features of a partial but more potent agonist than Dob on white adipocytes ( Figure 4c , Table 3 ).
The selective b 2 -agonist, Proc, stimulated lipolysis less potently than the catecholamines, the selective b 3 -agonists and Xam (Figure 4c , Table 3 ). The potencies of Proc and Dob were similar.
Eect of b-antagonists on lipolysis induced by dierent b-agonists
To characterize further the b-adrenoceptor subtypes involved in lipolysis, we studied the inhibition of the functional response by the selective b 1 -antagonist CGP 20712A and the selective b 2 -antagonist ICI 118551 ( Figure 5 , Tables 4 and 5 ). In Table 4 we show the results with agonists at concentrations promoting a nearly full lipolytic response (70 ± 100%). The data obtained with lower concentrations of the agonists (about b-Adrenoceptor subtype expression and functionthe EC 50 value), which induced a partial lipolytic response (50 ± 60%), are presented in Figure 5 . The use of lower doses minimized the lipolytic response mediated by the second and more abundant sites when the response was produced by two populations of sites. Analysis of the inhibition curves ( Figure  5 ) showed that a two site model ®tted the data better than a one site model for the results with Iso ( Figure 5a ) and NA ( Figure 5b ) with CGP 20712A as antagonist and Proc ( Figure  5f ) with both antagonists (P50.001). The IC 50 values are shown in Table 5 .
Catecholamines Iso-induced lipolysis was signi®cantly but slightly (23%) decreased by the selective b 1 -antagonist CGP 20712A at 10 mM but not signi®cantly aected by b 2 -antagonist, ICI 118551 1 mM (Table 4 ). This suggests that the majority (77%) of lipolysis was mediated by b 3 -adrenoceptors. CGP 20712A exhibited biphasic dose-response curves for inhibition of lipolysis induced by two b-agonists, Iso and NA (Figure 5a and b). The ®rst sites implicated in the induction of lipolysis represented 22+5% and 19+4%, respectively. CGP 20712A was at least 5000 times more potent as an inhibitor of the stimulating response mediated by the ®rst population than by the second population of sites (Table 5 ). In contrast, the inhibition curves obtained with ICI 118551 were monophasic and the potency of ICI 118551 was low (Figure 5a and b; Table  5 ). These data indicate that, in rat white adipocytes, the catecholamines, Iso and NA, induce lipolysis predominantly by stimulation of the b 3 -subtype and weakly by activation of b 1 -adrenoceptors.
Selective b (1 mM) on BRL (0.01 mM)-induced response were observed (Table 4) . ICI 118551 5 mM inhibited signi®cantly the BRLinduced lipolysis by 19%, raising the possibility that this antagonist can act on b 3 -adrenoceptors (Table 4) . When the concentration of BRL was lower (close to the EC 50 value) CGP 20712A had a partial inhibitory eect with weak potency (Figure 5c and Table 5 ). The IC 50 value for ICE 118551 inhibition was similar to the value obtained when lipolysis was stimulated by Iso or NA. The concentration-response curves for inhibition of BRL-induced lipolysis by both antagonists were monophasic. These results suggest strongly that BRL has a speci®c action on lipolysis through activation of b 3 -adrenoceptors only.
Selective b 1 -agonist CGP 20712A 10 mM inhibited Dob-and Xam-induced lipolysis powerfully (68% and 95%, respectively) whereas 1 mM ICI 118551 had no signi®cant eect (Table 4) . While studying the inhibition of the partial lipolytic response (Dob and Xam at lower concentration) by a full range of antagonist concentrations, the b 1 -selective antagonist was found to be more potent than the b 2 -selective antagonist (Figure 5d and e; Table 5 ). The IC 50 values for CGP 20712A were 10 and 70 times lower than those for ICI 118551 against the Dob-and Xam-induced responses, respectively. These results, and the fact that only one population of sites was implicated in the stimulation of lipolysis by these agonists, indicate a high selectivity of Xam and Dob for the b 1 -adrenoceptor subtype and this selectivity seems to be greater for Xam than for Dob.
Selective b 2 -agonist The results obtained with Proc were unexpected. The lipolysis induced by Proc (10 mM and 1 mM) was antagonized not only by ICI 118551 but also by CGP 20712A, a b 1 -antagonist (Table 4) . ICI 118551 1 mM inhibited the lipolysis produced by 1 mM Proc by 59%, whereas this inhibition was 39% with 10 mM Proc. The selective b 1 -antagonist suppressed the lipolysis induced by Proc 1 mM and 10 mM by 50% and 28%, respectively. The study of the inhibition of the lipolytic response by a range of concentrations of the antagonists showed that Proc-induced lipolysis was similarly antagonized not only by ICI 118551 but also by CGP 20712A (Figure 5f , Table 5 ). The heterogeneity of the inhibition curves indicates that at least two populations of sites were involved in the induction of lipolytic eect by Proc. Quantitative determination of percentage of the ®rst population to induce functional response represented 23+6% and 37+2% when CGP 20712A and ICI 118551 were used, respectively. The potency of CGP 20712A and ICI 118551 to inhibit lipolysis was 2500 and 250 times greater for the ®rst sites than for the second sites (Table  5) 
Discussion
Previous studies performed on rat white adipocyte membranes before the existence of the b 3 -adrenoceptor was accepted, showed that the binding of [ Table 2 ) (Bojanic & Nahorski, 1983; Bahout & Malbon, 1988) . Likewise, the same agents inhibited radioligand binding to the low anity sites with a potency order corresponding to that of the b 3 -subtype: BRL44Iso5NA4Ad (Emorine et al., 1989; Muzzin et al., 1991; Nahmias et al., 1991; Liggett, 1992) . All of our binding studies are in good agreement with the work of other laboratories. The K D values of high anity (0.22+0.07 nM) and low anity binding sites (27+5 nM) were in the same range as the corresponding K D s observed in human and garden dormouse white adipocytes (Revelli et al., 1993; CarpeÂ neÂ et al., 1994) , in homogenates of rat brown adipose tissue (Muzzin et al., 1992) CGP 12177 allows the characterization of the b 3 -subtype in rat white adipocytes as eectively as in other adipocyte types.
In our study the functional stimulations exhibited a similar potency order with agonists (BRL44Iso4NA4Ad) as previously described for rat and garden dormouse white adipocytes, and 3T3-F442A adipocytes (Figure 4 ; Table 3 ) (Hollenga et al., 1990; Langin et al., 1991; FeÁ ve et al., 1991; CarpeÂ neÂ et al., 1993; Bousquet-MeÂ lou et al., 1994) . Furthermore, the pD 2 values were in the same potency order as those found by the authors cited. In our experiments BRL was highly selective for b 3 -adrenoceptors on rat white adipocytes, since the response induced by a high concentration of this agonist was not blunted by 10 mM CGP 20712A (b 1 -antagonist) or 1 mM ICI 118551 (b 2 -antagonist) ( Table 4 ). In addition, the inhibition curves for both antagonists were monophasic and their activities were low (Figure 5c ; Table 5 ). These observations provide strong evidence that lipolysis is mainly mediated by the b 3 -subtype in rat white adipocytes. Consequently, CGP 12177 (b 1 -and b 2 -antagonist, partial b 3 -agonist) induced a partial lipolytic response in these cells as previously described (Hollenga & Zaagsma, 1989; Langin et al., 1991; Murphy et al., 1993; Van Liefde et al., 1993; Bousquet-MeÂ lou et al., 1994) .
The b 1 -subtype was identi®ed, not only by the potency order of BRL and catecholamines, but also by competition experiments conducted with Xam (selective b 1 -agonist) at a [ 3 H]-CGP 12177 concentration which labels all b-subtypes ( Figure 2c ; Table 2 ). Our data show the presence of a single homogeneous population of high anity binding sites. The (Malta et al., 1985; Brodde et al., 1990) , and for rat lung b 1 -adrenoceptors determined with [ 3 H]-DHA (Cook et al., 1984) . As Xam and Dob induced lipolysis in rat white adipocytes, the involvement of b 1 -adrenoceptors in this biological response is indicated (Figure 4c ; Table 3 ). Accordingly, Xaminduced lipolysis was blocked by the b 1 -adrenoceptorantagonist, CGP 20712A (Table 4 ). In contrast, ICI 118551 (selective b 2 -antagonist) did not counteract the response to Xam. The result obtained with Dob was similar, although the lipolytic response was not completely attenuated by CGP 20712A, suggesting the possible recruitment of other badrenoceptor subtypes. It is also possible that Dob, being a selective b 1 -agonist in vivo, lost this selectivity in vitro as described by Minneman et al. (1979) . The biphasic inhibition of Iso-and NA-induced lipolysis by CGP 20712A showed that the minor population of b-adrenoceptors was counteracted potently by this b 1 -antagonist (Figure 5a and b; Table  5) . Results from functional studies agree well with those from competition studies; they indicate a minor role for the b 1 -subtype in lipolysis activation similar to previous conclusions (Hollenga & Zaagsma, 1989; Van Liefde et al., 1992; Murphy et al., 1993; Bousquet-MeÂ lou et al., 1994) .
To evaluate the presence of the b 2 -subtype, the inhibition of Table 2 ). A single homogeneous population of b-adrenoceptors with low anity was identi®ed. The density of these sites was similar to that obtained with Xam, a selective b 1 -agonist. The Proc K i value for human cardiac b 1 -adrenoceptors was 10.3 mM, whereas for human lung and lymphocyte b 2 -receptors this constant was 0.122 mM and 0.079 mM, respectively (Brodde et al., 1990) , indicating a 100 times greater potency for b 2 -than for b 1 -receptors. Thus, we believe that Proc competed only with b 1 -adrenoceptors in rat white adipocytes and b 2 -receptors were not detectable. The same result was obtained on rat brown adipocytes (D'Allaire et al., 1995) . Bojanic and Nahorski (1983) using [ 125 I]-CYP compared the presence of b 1 -and b 2 -subtypes on rat whole fat pad and isolated adipocyte membranes. They concluded that, in view of the proportion of b 2 -adrenoceptors on whole fat pads (62%) and adipocytes (15%), their presence might re¯ect contamination from other cell types, especially as the rank order of b-agonist potencies (Iso4NA4Ad) indicated the presence of the b 1 -subtype.
Our functional studies suggest that b 2 -adrenoceptors could play a minor role in mediating lipolysis since Proc, b 2 -agonist, was able to induce the lipolytic response with a potency (2570 nM) close to that (3330 nM) observed by Bousquet-MeÂ -lou et al. (1994) in the same cells (Figure 4c ; Table 3 ). The potency of Proc in white adipocytes was very low in comparison to the tissues containing high amounts of the b 2 -adrenoceptors, approximately 1 nM (Yabuuchi, 1977; Cook et al., 1993) . In our study, performed on rat white adipocytes, 1 mM ICI 118551 partially inhibited Proc-induced lipolysis, whereas on dog white adipocytes, at the same Proc concentration, the lipolytic response was totally abolished and the Proc EC 50 value was 62 nM (Table 4) (Galitzky et al., 1993) . These observations indicate a species dierence in the expression of badrenoceptor subtypes.
The inhibition curves of Proc-induced lipolysis at a concentration close to the EC 50 value by both antagonists were biphasic (Figure 5f ; Table 5 ). Lipolysis mediated by the ®rst population of sites represented 23% when CGP 20712A antagonized the response induced by this b 2 -agonist as a similar result was obtained when Iso and NA were used as agonists. These data indicate the recruitment of the b 1 -subtype in the functional response produced by Proc. The similar inhibition of Proc-, Iso-and NA-induced lipolysis by CGP 20712A via the second and major population of b-adrenoceptors suggests the participation of the b 3 -subtype in the functional response produced by this b 2 -agonist. ICI 118551 inhibited by 37% and with high potency the functional response of Proc mediated by the ®rst population of sites. In contrast, the functional inhibition of the eects of NA and Iso by this antagonist was monophasic with low potency. These data suggest that this b 2 -antagonist did not distinguish between b 1 -and b 3 -adrenoceptors. We conclude that Proc triggered lipolysis by stimulation of the three b-subtypes. All these observations indicate that, in rat white adipocytes, the b 2 -subtype represents a very small population of b-adrenoceptors and that in physiological conditions the b 2 -subtype is probably not implicated in the stimulation of lipolysis.
In conclusion, the radioligand [ 3 H]-CGP 12177 can be used to characterize two b-adrenoceptor subtypes, b 1 and b 3 on rat white adipocytes, as found for other types of adipocytes. [
3 H]-CGP 12177 is, therefore, a suitable tool for the exploration of b-subtypes in various physiological or pathological situations, and it has been used to assess the eect of triiodothyronine on rat white adipocytes (Germack et al., 1996) . Moreover, the three b-adrenoceptor subtypes are functional in rat white adipocytes, whereas the b 2 -subtype represents the smallest population of b-adrenoceptors which was not detectable by binding studies. The overall response is essentially dependent on b 1 -and b 3 -receptors. Finally, the good relationship between functionality and identity of b-subtypes con®rmed that lipolysis is mainly driven by the b 3 -subtype in rat white adipocytes. We propose that the rank order of expression and capacity to induce lipolysis is b 3 44b 1 4b 2 .
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